saracatinib

Known as: 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, N-(5-Chloro-1,3-Benzodioxol-4-Yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Oxan-4-yl)Oxy)Quinazolin-4-Amine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine 
An orally available 5-, 7-substituted anilinoquinazoline with anti-invasive and anti-tumor activities. Saracatinib is a dual-specific inhibitor of… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2009-2017
05101520092017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
The phenotypic transformation of well-differentiated epithelial carcinoma into a mesenchymal-like state provides cancer cells… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2013
2013
Saracatinib, a highly selective, dual Src/Abl kinase inhibitor, is currently in a Phase II clinical trial for the treatment of… (More)
Is this relevant?
2012
2012
PURPOSE Dysregulation of the phosphoinositide 3-kinase (PI3K) and Src signaling pathways commonly occur in colorectal cancer… (More)
Is this relevant?
2012
2012
PURPOSE More effective, less toxic treatments for recurrent ovarian cancer are needed. Although more than 60% of ovarian cancers… (More)
Is this relevant?
2011
2011
BACKGROUND SRC activation is associated with cell migration, proliferation, and metastasis. Saracatinib is an oral tyrosine… (More)
Is this relevant?
2011
2011
BACKGROUND Saracatinib (AZD0530) is an orally available Src kinase inhibitor. A phase II study was conducted to evaluate… (More)
  • table I
  • table II
  • figure 1
Is this relevant?
2010
2010
Src is a nonreceptor tyrosine kinase thought to be essential for osteoclast function and bone resorption. We investigated the… (More)
Is this relevant?
2010
2010
BACKGROUND Src, a non-receptor tyrosine kinase frequently overexpressed and highly activated in malignancies, has been associated… (More)
Is this relevant?
2010
2010
PURPOSE This dose-escalation study evaluated the safety, tolerability, and pharmacokinetics (PK) of the oral Src inhibitor… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
Elevated Src kinase activity is linked to the progression of solid tumors, including head and neck squamous cell carcinoma (HNSCC… (More)
Is this relevant?